Catalyst
Slingshot members are tracking this event:
Alkermes ALKS 8700 for the treatment of multiple sclerosis expected to submit NDA in 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALKS |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 17, 2018
Occurred Source:
https://www.prnewswire.com/news-releases/alkermes-and-biogen-announce-submission-of-a-new-drug-application-to-us-food-and-drug-administration-for-diroximel-fumarate-in-multiple-sclerosis-300767188.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Multiple Sclerosis
